Thrombosis in multiple myeloma (MM)

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Cesarman Maus, Gabriela ^a   Braggio, Esteban ^b   Fonseca, Rafael ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b MAYO CLINIC   (United States)

Author keywords

Multiple myeloma; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; ANTIVITAMIN K; BORTEZOMIB; DEXAMETHASONE; ERYTHROPOIETIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; PROTEASOME INHIBITOR; THALIDOMIDE; WARFARIN;

BLEEDING RISK; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LOW DRUG DOSE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, HORMONAL; DEXAMETHASONE; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; THALIDOMIDE; THROMBOSIS;

EID: 84859791294     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169156933     Document Type: Review

References (33)

1. Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev. 2010;36 Suppl 2:S24-32.
2. Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood. 2010;116(1):22-6.
3. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78(5):285-91.
4. Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis. 2007;18:595-8.
5. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010;28:132-5.
6. Boccaccio P, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol. 2009;27:4827-33.
7. Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracyclinebased chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80(12):1568-74.
8. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006;108:403.
9. Niesvizky R, Martinez-Baños D, Jalbrikowski J, Christos P, Furst J, de Sancho M, et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma. 2007;48(12):2330-7.
10. Niesvizky R, Martinez-Baños D. Aspirin as thromboprophylaxis in myeloma. Leuk Lymphoma. 2008;49(8):1646-7.
11. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986-93.
12. Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010;115(3):605-14.
13. Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Björkholm M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112:3582-6.
14. Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991-8.
15. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187-92.
16. van Marion AM, Auwerda JJ, Minnema MC, van Oosterom R, Adelmeijer J, de Groot PG, et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost. 2005;94(6):1341-3.
17. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006;134(4):399-405.
18. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558-66.
19. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943-9.
20. Carrier M, Le Gal J, Tay C, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011;9(4):653-66.
21. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-2.
22. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29-3.
23. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Blood. 2008;15;112(8):3107-14.
24. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168-71.
25. Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB, et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer. 2011;118:549-57.
26. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986-93.
27. Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomidebased therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011;11(2):228-36.
28. Zhang L, Zhang ZG, Liu X, Hozeska A, Stagliano N, Riordan W, et al. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost. 2006;95(1):166-73.
29. Avcu F, Ural AU, Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res. 2008;121(4):567-71.
30. Montiel-Manzano G, Romay-Penabad Z, Papalardo de Martinez E, Meillon-García LA, García-Latorre E, Reyes-Maldonado E, et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann NY Acad Sci. 2007;1108:540-53.
31. Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol. 2009;27:4848-57.
32. Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K, et al. Lenalidomide and pegylated liposomal doxorubicinbased chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006;17:1766-71.
33. Saif MW, Allegra CJ, Greenberg B. Bleeding diathesis in multiple myeloma. J Hematother Stem Cell Res. 2001;10(5):657-60.